The idea of targeting the neuropilin-1 receptor has already been highlighted in two studies, which found that NRP1 blockade suppresses angiogenesis and medulloblastoma regression, decreases the rate of metastasis, and leads to better oncological outcomes in treated mice [17,18]. The gene discussed is NRP1; the disease is medulloblastoma.